These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22481387)

  • 1. Panel backs pain drug studies with new safety checks.
    Dolgin E
    Nat Med; 2012 Apr; 18(4):472. PubMed ID: 22481387
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 3. The impact of escalating regulatory requirements on the conduct of clinical research.
    Gordon BG; Kessinger A; Mann SL; Prentice ED
    Cytotherapy; 2003; 5(4):309-13. PubMed ID: 12944237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoepidemiology 101: data monitoring committees in the post-marketing approval setting.
    Lilienfeld DE
    Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):381-5. PubMed ID: 15170767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety panel backs principle of gene-therapy trials.
    Check E
    Nature; 2002 Dec; 420(6916):595. PubMed ID: 12478252
    [No Abstract]   [Full Text] [Related]  

  • 6. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulatory perspectives on data monitoring.
    O'Neill RT
    Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential safety signals and their significance.
    Powers A; Cook GE
    Arch Intern Med; 2012 Jan; 172(1):72-3. PubMed ID: 22082712
    [No Abstract]   [Full Text] [Related]  

  • 9. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
    Ellenberg SS; George SL
    Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA
    Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
    [No Abstract]   [Full Text] [Related]  

  • 11. Dietary supplements: a call to action.
    Lipman AG
    J Pain Palliat Care Pharmacother; 2010 Dec; 24(4):330-2. PubMed ID: 21133740
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 150 years of pharmacovigilance.
    Routledge P
    Lancet; 1998 Apr; 351(9110):1200-1. PubMed ID: 9643710
    [No Abstract]   [Full Text] [Related]  

  • 15. Failing the public health--rofecoxib, Merck, and the FDA.
    Topol EJ
    N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193
    [No Abstract]   [Full Text] [Related]  

  • 16. Proposal to improve MedWatch: decentralized, regional surveillance of adverse drug reactions.
    Motl S; Timpe E; Eichner S
    Am J Health Syst Pharm; 2004 Sep; 61(17):1840-2. PubMed ID: 15462254
    [No Abstract]   [Full Text] [Related]  

  • 17. New FDA regulation to improve safety reporting in clinical trials.
    Sherman RB; Woodcock J; Norden J; Grandinetti C; Temple RJ
    N Engl J Med; 2011 Jul; 365(1):3-5. PubMed ID: 21651388
    [No Abstract]   [Full Text] [Related]  

  • 18. A challenge to the data miners.
    Lilienfeld DE;
    Pharmacoepidemiol Drug Saf; 2004 Dec; 13(12):881-4. PubMed ID: 15558812
    [No Abstract]   [Full Text] [Related]  

  • 19. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005.
    Moore TJ; Cohen MR; Furberg CD
    Arch Intern Med; 2007 Sep; 167(16):1752-9. PubMed ID: 17846394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between pathologic gambling and parkinsonian therapy as detected in the Food and Drug Administration Adverse Event database.
    Szarfman A; Doraiswamy PM; Tonning JM; Levine JG
    Arch Neurol; 2006 Feb; 63(2):299-300; author reply 300. PubMed ID: 16476828
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.